Evidence map›Paper›PMID 38989563›Full record

ArticleProtein science : a publication of the Protein Society2024

Complete combinatorial mutational enumeration of a protein functional site enables sequence-landscape mapping and identifies highly-mutated variants that retain activity.

Mireia Solà Colom, Jelena Vučinić, Jared Adolf-Bryfogle, James W Bowman, Sébastien Verel, Isabelle Moczygemba, Thomas Schiex, David Simoncini, Christopher D Bahl

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Mireia Solà ColomInstitute for Protein Innovation, Boston, Massachusetts, USA.
Jelena VučinićUniversité Fédérale de Toulouse, IRIT UMR 5505, ANITI, Université Toulouse Capitole, Toulouse, France.
Jared Adolf-BryfogleInstitute for Protein Innovation, Boston, Massachusetts, USA.
James W BowmanInstitute for Protein Innovation, Boston, Massachusetts, USA.
Sébastien VerelLISIC UR 4491, Université Littoral Côte d'Opale, Calais, France.
Isabelle MoczygembaInstitute for Protein Innovation, Boston, Massachusetts, USA.
Thomas SchiexMIAT, Université Fédérale de Toulouse, ANITI, INRAE UR 875, Toulouse, France.
David SimonciniUniversité Fédérale de Toulouse, IRIT UMR 5505, ANITI, Université Toulouse Capitole, Toulouse, France.
Christopher D BahlInstitute for Protein Innovation, Boston, Massachusetts, USA.

Funding

Computational de novo design of a disulfide-rich miniprotein synthetic library and its application to engineer binders to neutralizing epitopes on Clostridium difficile toxins TcdA and TcdBR21AI156570 · NIAID · INSTITUTE FOR PROTEIN INNOVATION, INC. · PI BAHL, CHRISTOPHER DAVID · 2021 to 2022
$452k
De novo design of generalizable allosteric modulators and peptide ligands for G protein coupled receptorsR21EB028342 · NIBIB · INSTITUTE FOR PROTEIN INNOVATION, INC. · PI BAHL, CHRISTOPHER DAVID · 2020 to 2021
$413k
Agence Nationale de la Recherche ANR-20-CE45-0016Artificial and Natural Intelligence Toulouse Institute ANR-19-P3IA-0004National Science Foundation 2031785NIAID NIH HHS R21 AI156570NIBIB NIH HHS R21 EB028342NIH HHS R21 AI156570NIH HHS R21 EB028342
6 · The paper itself

Abstract

Understanding how proteins evolve under selective pressure is a longstanding challenge. The immensity of the search space has limited efforts to systematically evaluate the impact of multiple simultaneous mutations, so mutations have typically been assessed individually. However, epistasis, or the way in which mutations interact, prevents accurate prediction of combinatorial mutations based on measurements of individual mutations. Here, we use artificial intelligence to define the entire functional sequence landscape of a protein binding site in silico, and we call this approach Complete Combinatorial Mutational Enumeration (CCME). By leveraging CCME, we are able to construct a comprehensive map of the evolutionary connectivity within this functional sequence landscape. As a proof of concept, we applied CCME to the ACE2 binding site of the SARS-CoV-2 spike protein receptor binding domain. We selected representative variants from across the functional sequence landscape for testing in the laboratory. We identified variants that retained functionality to bind ACE2 despite changing over 40% of evaluated residue positions, and the variants now escape binding and neutralization by monoclonal antibodies. This work represents a crucial initial stride toward achieving precise predictions of pathogen evolution, opening avenues for proactive mitigation.

Indexed as

Angiotensin-Converting Enzyme 2MutationSARS-CoV-2Spike Glycoprotein, CoronavirusArtificial IntelligenceBinding SitesCOVID-19HumansProtein BindingACE2 protein, humanAngiotensin-Converting Enzyme 2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2artificial intelligenceevolutionneutralizing antibodyprotein bindingprotein designprotein structureSARS‐CoV‐2structure predictionvirology

Identifiers

PMID38989563
PMCPMC11237556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.